Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2290-2296

  Jung, Sang Hoon ^a   Kim, Kyung A ^a   Sohn, Sea Woon ^b   Yang, Sung Jae ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Aqueous humor; Cytokines; Retina ischemia; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NEOVASCULAR GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; VISUAL ACUITY;

AQUEOUS HUMOR; CYTOKINES; RETINA ISCHEMIA; RETINAL VEIN OCCLUSION;

AQUEOUS HUMOR; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; ISCHEMIA; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84898403810     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13587     Document Type: Article

References (38)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-141, discussion 141-133.
2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111-131.
3. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117: 429-441.
4. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90:488-506.
5. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica. 2010;224(suppl 1):8-15.
6. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412-416.
7. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22:42-48.
8. Fonollosa A, Garcia-Arumi J, Santos E, et al. Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. Eye (Lond). 2010;24:1284-1290.
9. Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90:e98-e103.
10. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
11. Noma H, Funatsu H, Mimura T. Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. J Ocul Pharmacol Ther. 2013;29:363-365.
12. Lin JM, Chiu YT, Hung PT, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide. Retina. 2007;27: 180-189.
13. Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97:1040-1044.
14. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol. 2007;245:1429-1436.
15. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19:234-238.
16. Noma H, Funatsu H, Mimura T, Harino S, Sone T, Hori S. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol. 2010;88:646-651.
17. Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol. 2013;131:160-165.
18. Kaneda S, Miyazaki D, Sasaki S, et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci. 2011;52:2982-2988.
19. Okunuki Y, Usui Y, Katai N, et al. Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol. 2011;151:610-616.
20. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116:87-93.
21. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244: 309-315.
22. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol. 2010;20:402-409.
23. Stahl A, Buchwald A, Martin G, et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina. 2010;30:1524-1529.
24. Noma H, Funatsu H, Harino S, Nagaoka T, Yamashita H, Hori S. [Pathogenesis of macular edema associated with branch retinal vein occlusion and strategy for treatment]. Nihon Ganka Gakkai Zasshi. 2010;114:577-591.
25. Holzinger C, Weissinger E, Zuckermann A, et al. Effects of interleukin-1,-2,-4,-6, interferon-gamma and granulocyte/ macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett. 1993;35:109-117.
26. Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest. 1996;97:1931-1941.
27. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258:1798-1801.
28. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol. 1995;57:752-762.
29. Elner SG, Strieter R, Bian ZM, et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:1597-1601.
30. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferoninducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995;182:155-162.
31. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295-4301.
32. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
33. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood. 2005;105:1405-1407.
34. Voskuil M, van Royen N, Hoefer IE, et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol. 2003;284: H1422-1428.
35. Wilkinson-Berka JL, Babic S, De Gooyer T, et al. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol. 2004;164: 1263-1273.
36. McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand). 2001;47:619-635.
37. Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117-144.
38. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437:497-504.